Company intelligence / Profile preview
Guilin Sanjin Pharmaceutical Co., Ltd.
Guilin, Guangxi Zhuang Autonomous Region, Chinasanjin.com.cn ↗
- Ownership
- Public · 002275
- Employees
- ~2615
- Development stage
- Commercial
01
Overview
Guilin Sanjin has multiple approved products in China including GuiLinXiGuaShuang, SanJin Tablets, XuanYunNing, and XiGuaShuangRunHou. The company has 9 biologics candidates in its pipeline with 4 in clinical development stage.
- Therapeutic areas
- Men's HealthPulmonologyOncologyImmunologyOtherNeurologyGastroenterologyNephrologyInfectious Diseases
- Modalities
- Traditional Chinese MedicineNatural MedicineHerbal MedicineMonoclonal AntibodyBispecific AntibodyBiosimilar
- Industry
- Biotech
02
Drug pipeline
16 assets15 more assets in the full pipeline.
03
Financials
- Market cap
- $1.5B
- Total revenue
- $306.7M
- Enterprise value
- $1.3B
Beyond the preview
Go deeper on Guilin Sanjin Pharmaceutical Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Guilin Sanjin Pharmaceutical Co., Ltd..